Open an account

Compass Pathways

CMPS · NASDAQ

$11.90+$0.79 (+7.11%)TodayMarket closed ·
Prev close $11.11

About CMPS

Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 156 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Employees
156
Headquarters
Altrincham, Cheshire
Listed
Sep 18, 2020
Sector
Health Care
Industry
Biotechnology
Website
compasspathways.com

CMPS key statistics

Market cap
1.54B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.86M
Volume
3.35M
Open price
$11.11
High today
$12.04
Low today
$11.07
52 Week high
$15.87
52 Week low
$4.88

Compass Pathways (CMPS) at a glance

Compass Pathways (CMPS) last traded at $11.90, with a market cap of 1.54B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.07 and $12.04. The current price is 7.5% above the day's low and 1.2% below its high.

Volume so far is 3.35M shares, in line with the average of 2.86M shares a day.

Over the past year Compass Pathways has ranged from $4.88 to $15.87, and now sits 64% of the way up that range.

Compass Pathways met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$1.88 per share against an estimate of -$0.4051.

The average analyst price target is $22.41, 88.3% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 13 analyst ratings say Buy
  • Buy92.3%
  • Hold7.7%
  • Sell0.0%
Price target · 20 analystsAvg $22.41
Low
$13.13
Now
$11.90
High
$68.25

CMPS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 63.3% on average.

  1. Q3 FY24: reported -$0.56 per share against an estimate of -$0.5825
  2. Q4 FY24: reported -$0.63 per share against an estimate of -$0.6446
  3. Q1 FY25: reported -$0.38 per share against an estimate of -$0.4771
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.4366
  5. Q3 FY25: reported -$1.44 per share against an estimate of -$0.3978
  6. Q4 FY25: reported -$1.00 per share against an estimate of -$0.4023
  7. Q1 FY26: reported $0.71 per share against an estimate of -$0.3856
  8. Q2 FY26: reported -$1.88 per share against an estimate of -$0.4051

CMPS news

  • Press releaseBusiness Wire

    Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

  • Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript

  • Press releaseBusiness Wire

    Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Press releaseBusiness Wire

    Compass Pathways Appoints Kelley Boucher as Chief People Officer

  • Press releaseBusiness Wire

    Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

  • Press releaseBusiness Wire

    Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

  • Press releaseBusiness Wire

    Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

  • Press releasePRNewswire

    Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Similar companies

Companies in the same industry as Compass Pathways

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.